{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:05:48Z","timestamp":1754111148212,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11912-023-01404-6","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:03:20Z","timestamp":1682499800000},"page":"841-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting"],"prefix":"10.1007","volume":"25","author":[{"given":"Sean","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"25","key":"1404_CR1","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331.","journal-title":"Blood"},{"key":"1404_CR2","unstructured":"Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961\u20138.\u00a0Manuscript describes the impact of fludarabine dosing on outcomes, supporting the vital role to supplement appropriately when fludarabine is unavailable."},{"issue":"7","key":"1404_CR3","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6(7):1969\u201376.","journal-title":"Blood Adv"},{"key":"1404_CR4","doi-asserted-by":"crossref","unstructured":"Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33(9):916\u201328.\u00a0Manuscript establishes bendamustine as an effective, safe LD option prior to CAR T cell therapy.","DOI":"10.1016\/j.annonc.2022.05.521"},{"issue":"1","key":"1404_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"12","key":"1404_CR6","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917\u201323.","journal-title":"J Clin Oncol"},{"key":"1404_CR7","doi-asserted-by":"crossref","unstructured":"Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children\u2019s Oncology Group study AALL1131. Cancer. 2018;124(6):1150\u20139.\u00a0Manuscript describes clofarabine use and toxicities in pediatric ALL setting.","DOI":"10.1002\/cncr.31099"},{"issue":"6","key":"1404_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","journal-title":"J Clin Invest"},{"key":"1404_CR9","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","DOI":"10.1126\/scitranslmed.aaf8621"},{"issue":"26","key":"1404_CR10","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134(26):2361\u20138.","journal-title":"Blood"},{"issue":"8 Suppl 19","key":"1404_CR11","first-page":"1","volume":"9","author":"BD Cheson","year":"2011","unstructured":"Cheson BD, Leoni L. Bendamustine: mechanism of action and clinical data. Clin Adv Hematol Oncol. 2011;9(8 Suppl 19):1\u201311.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1404_CR12","unstructured":"Pharmaceuticals C. Treanda highlights of prescribing information. 2008."},{"key":"1404_CR13","doi-asserted-by":"crossref","unstructured":"Vinti L, Pagliara D, Buffardi S, Di Ruscio V, Stocchi F, Mariggio E, et al. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Pediatr Blood Cancer. 2022;69(4):e29557. Manuscript establishes that bendamustine can be used safely in the pediatric setting.","DOI":"10.1002\/pbc.29557"},{"key":"1404_CR14","doi-asserted-by":"crossref","unstructured":"Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A, et al. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed\/refractory Hodgkin lymphoma. Blood Adv. 2021;5(24):5519\u201324.\u00a0Manuscript establishes that bendamustine can be used safely in the pediatric setting.","DOI":"10.1182\/bloodadvances.2021005268"},{"issue":"32","key":"1404_CR15","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1404_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nrd2055","volume":"5","author":"PL Bonate","year":"2006","unstructured":"Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA 3rd, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5(10):855\u201363.","journal-title":"Nat Rev Drug Discov"},{"issue":"1\u20132","key":"1404_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/15257770008033020","volume":"19","author":"WR Waud","year":"2000","unstructured":"Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids. 2000;19(1\u20132):447\u201360.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1404_CR18","unstructured":"Sanofi-Aventis. Clolar highlights of prescribing information. 2014."},{"issue":"7","key":"1404_CR19","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","volume":"102","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379\u201386.","journal-title":"Blood"},{"issue":"3","key":"1404_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","volume":"147","author":"F Locatelli","year":"2009","unstructured":"Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009;147(3):371\u20138.","journal-title":"Br J Haematol"},{"key":"1404_CR21","doi-asserted-by":"crossref","unstructured":"Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, et al. Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy-only cytoreduction with clofarabine, melphalan, and thiotepa. Biol Blood Marrow Transplant. 2016;22(8):1449\u201354.\u00a0Manuscript describes clofarabine use and toxicities in pediatric HSCT setting.","DOI":"10.1016\/j.bbmt.2016.05.001"},{"issue":"1","key":"1404_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","volume":"33","author":"J Floyd","year":"2006","unstructured":"Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50\u201367.","journal-title":"Semin Oncol"},{"issue":"4","key":"1404_CR23","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200\u20137.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1404_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","volume":"41","author":"SM Yule","year":"1996","unstructured":"Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol. 1996;41(1):13\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1404_CR25","unstructured":"Baxter. Cyclophosphamide highlights of prescribing information. 2013."},{"issue":"6","key":"1404_CR26","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3109\/10428194.2013.836600","volume":"55","author":"BL Nordstrom","year":"2014","unstructured":"Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, Sterchele JA. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. Leuk Lymphoma. 2014;55(6):1266\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1404_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","volume":"66","author":"JS Owen","year":"2010","unstructured":"Owen JS, Melhem M, Passarell JA, D\u2019Andrea D, Darwish M, Kahl B. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin\u2019s lymphoma. Cancer Chemother Pharmacol. 2010;66(6):1039\u201349.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1404_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","volume":"75","author":"M Darwish","year":"2015","unstructured":"Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015;75(6):1143\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1404_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41409-018-0260-z","volume":"54","author":"H Chung","year":"2019","unstructured":"Chung H, Hong KT, Lee JW, Rhee SJ, Kim S, Yoon SH, et al. Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. Bone Marrow Transplant. 2019;54(2):284\u201392.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1404_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","volume":"41","author":"V Gandhi","year":"2002","unstructured":"Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93\u2013103.","journal-title":"Clin Pharmacokinet"},{"key":"1404_CR31","unstructured":"Sandoz. Fludarabine highlights of prescribing information. 2010."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01404-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T08:58:57Z","timestamp":1688633937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01404-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1404"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01404-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"type":"print","value":"1523-3790"},{"type":"electronic","value":"1534-6269"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"13 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}